Insider Selling: Apogee Therapeutics, Inc. (NASDAQ:APGE) Insider Sells 1,590 Shares of Stock

Apogee Therapeutics, Inc. (NASDAQ:APGE) insider Carl Dambkowski sold 1,590 shares of the stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $30.48, for a total transaction of $48,463.20. Following the transaction, the insider now owns 251,033 shares in the company, valued at approximately $7,651,485.84. The trade was a 0.63 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Carl Dambkowski also recently made the following trade(s):

• On Wednesday, February 5th, Carl Dambkowski sold 3,520 shares of Apogee Therapeutics stock. The stock was sold at an average price of $40.69, for a total transaction of $143,228.80.
• On Thursday, January 2nd, Carl Dambkowski sold 4,085 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.94, for a total transaction of $191,749.90.
• On Wednesday, December 11th, Carl Dambkowski sold 4,540 shares of Apogee Therapeutics stock. The stock was sold at an average price of $48.76, for a total transaction of $221,370.40.

Apogee Therapeutics Price Performance

Shares of NASDAQ:APGE opened at $36.14 on Friday. The company has a market cap of $1.63 billion, a price-to-earnings ratio of -14.93 and a beta of 2.46. The firm has a 50 day simple moving average of $38.92 and a 200 day simple moving average of $46.91. Apogee Therapeutics, Inc. has a one year low of $29.10 and a one year high of $72.29.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings data on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing the consensus estimate of ($0.94) by ($0.25). As a group, analysts expect that Apogee Therapeutics, Inc. will post -3.09 EPS for the current year.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Wedbush reiterated an “outperform” rating and set a $90.00 price target on shares of Apogee Therapeutics in a research report on Monday, March 3rd. Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target on the stock. Guggenheim reissued a “buy” rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Finally, Canaccord Genuity Group started coverage on shares of Apogee Therapeutics in a research note on Monday, November 25th. They issued a “buy” rating and a $89.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $91.60.

Hedge Funds Weigh In On Apogee Therapeutics

Several large investors have recently modified their holdings of APGE. GF Fund Management CO. LTD. bought a new position in shares of Apogee Therapeutics during the fourth quarter valued at $43,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Apogee Therapeutics during the third quarter valued at $71,000. Optimize Financial Inc bought a new position in shares of Apogee Therapeutics during the fourth quarter valued at $203,000. Aigen Investment Management LP bought a new position in shares of Apogee Therapeutics during the fourth quarter valued at $216,000. Finally, BNP Paribas Financial Markets bought a new position in shares of Apogee Therapeutics during the fourth quarter valued at $219,000. Institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.